50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The 3-Stock Retirement Blueprint (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The 3-Stock Retirement Blueprint (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The 3-Stock Retirement Blueprint (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The 3-Stock Retirement Blueprint (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
NASDAQ:ZSAN

Zosano Pharma - ZSAN Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$0.11
$0.15
50-Day Range
$0.52
$112.00
52-Week Range
$0.46
$37.45
Volume
11,627 shs
Average Volume
425,375 shs
Market Capitalization
$582,725.25
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ZSAN stock logo

About Zosano Pharma (NASDAQ:ZSAN) Stock

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Receive ZSAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zosano Pharma and its competitors with MarketBeat's FREE daily newsletter.

ZSAN Stock News Headlines

Zosano Pharma Corp (ZSANQ)
Zosano Pharma Reports Q1 Net Loss of $33.4M
Zosano Pharma Provides Corporate Update
See More Headlines

Receive ZSAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zosano Pharma and its competitors with MarketBeat's FREE daily newsletter.

ZSAN Company Calendar

Last Earnings
5/13/2022
Today
9/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZSAN
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Net Income
$-29,920,000.00
Net Margins
-8,375.11%
Pretax Margin
-8,375.11%

Debt

Sales & Book Value

Annual Sales
$790,000.00
Book Value
$9.74 per share

Miscellaneous

Free Float
4,784,000
Market Cap
$582,725.25
Optionable
Not Optionable
Beta
3.30

Key Executives

  • Mr. Steven  LoMr. Steven Lo (Age 55)
    Sr. VP of Operations, Pres, CEO & Director
    Comp: $534.08k
  • Ms. Christine Matthews (Age 53)
    Chief Financial Officer
    Comp: $312.45k
  • Dr. Donald J. Kellerman (Age 67)
    VP of Clinical Devel. & Medical Affairs
    Comp: $376.17k
  • Ms. Lu Liu
    VP of Technical Operations
  • Jeffrey L. Quillen
    Sec.
  • Ms. Kristina Warga
    VP & Corp. Controller













ZSAN Stock - Frequently Asked Questions

Should I buy or sell Zosano Pharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZSAN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZSAN, but not buy additional shares or sell existing shares.
View ZSAN analyst ratings
or view top-rated stocks.

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Co. (NASDAQ:ZSAN) announced its quarterly earnings data on Friday, May, 13th. The biotechnology company reported ($1.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.75) by $0.01. Zosano Pharma had a negative net margin of 8,375.11% and a negative trailing twelve-month return on equity of 177.06%.

When did Zosano Pharma's stock split?

Shares of Zosano Pharma reverse split on Tuesday, April 12th 2022. The 1-35 reverse split was announced on Tuesday, April 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Zosano Pharma own?
When did Zosano Pharma IPO?

(ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.

What is Zosano Pharma's stock symbol?

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

What is Zosano Pharma's stock price today?

One share of ZSAN stock can currently be purchased for approximately $0.12.

How much money does Zosano Pharma make?

Zosano Pharma (NASDAQ:ZSAN) has a market capitalization of $582,725.25 and generates $790,000.00 in revenue each year. The biotechnology company earns $-29,920,000.00 in net income (profit) each year or ($14.5034) on an earnings per share basis.

How can I contact Zosano Pharma?

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The official website for the company is www.zosanopharma.com. The biotechnology company can be reached via phone at (510) 745-1200 or via email at ir@paymentdata.com.

This page (NASDAQ:ZSAN) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.